{
  "docId": "019de071-1bdd-70bb-9c61-980d0c38b663",
  "docSlug": "a4792f18c57ea3f4ba27e696a63520de",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 40 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.4148858,
  "pageNumber": 22,
  "pageCount": 40,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "comparison_table",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 3,
  "notes": "The slide uses a grid layout to map drug indications against patient segments and treatment lines.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-1bdd-70bb-9c61-980d0c38b663/22",
  "deckHref": "/decks/019de071-1bdd-70bb-9c61-980d0c38b663",
  "deckJsonHref": "/decks/019de071-1bdd-70bb-9c61-980d0c38b663.json",
  "deckAnchorHref": "/decks/019de071-1bdd-70bb-9c61-980d0c38b663#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.62,
        "w": 0.92,
        "x": 0.04,
        "y": 0.28
      },
      "kind": "chart",
      "text": "Matrix of breast cancer treatments by patient type and line of therapy",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5a59ce7e-4596-43e2-92e1-fe4dd065caad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.25,
        "x": 0.72,
        "y": 0.82
      },
      "kind": "source-note",
      "text": "1. HER2-low prevalence is anticipated to be c.35-40% in TNBC 2. Antibody drug conjugates (Enhertu and datopotamab deruxtecan) 3. Immunotherapy 4. Chemotherapy.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "019e2ebb-4b99-496e-a013-8c409f7c8a29",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.85,
        "x": 0.04,
        "y": 0.2
      },
      "kind": "title",
      "text": "Potential to cover most patients across settings and lines of treatment",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ad4e22ba-cf7a-4196-aed7-d1e4e659f5b3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.04,
        "y": 0.14
      },
      "kind": "title",
      "text": "Breast cancer: well-positioned with at least six medicines",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "01e56120-d007-4a6a-b756-90f9ac8655bc",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "market-segmentation-pyramid",
      "slug": null,
      "matchId": "35a9cae6-7394-4bbc-bff5-b4744979fd81",
      "evidence": "The slide segments patients by disease type (HER2+, HR+, TNBC) and treatment line.",
      "confidence": 0.7
    }
  ],
  "arcBeats": [
    {
      "to": 40,
      "from": 21,
      "beatId": "9bb24be0-c8c7-49aa-a526-e9fcc4794b51",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The document concludes with a call to action and next steps for investors.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 28,
      "from": 21,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "cde01b8e-53ce-45e4-b3c4-d519c08ca374",
      "evidence": "The document implies that not investing in oncology would result in missed opportunities for growth and patient benefit.",
      "position": 1,
      "objective": "What are the consequences of not investing in oncology?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}